Dynamics of Hepatitis B Immunity After Kidney Transplantation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1130; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Among immune patients, alemtuzumab vs basiliximab showed higher loss (16.4% vs 10.7%; RR 1.53, 95% CI 0.85–2.76). Higher pre-transplant HBsAb levels predicted more durable protection, suggesting targets above ≥10 mIU/mL. Findings support routine antibody monitoring and improved vaccination as HBV NAT+ donor use increases."
Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation
|
|
Meshaal Alanzi; Holenarasipur R. Vikram; Hugo E. Vargas; Caroline Jadlowiec; Hasan Khamash; Sami Alasfar
|